FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2559999242> ?p ?o ?g. }

• W2559999242 abstract "Abstract Allogeneic stem cell transplantation offers curative therapy for many patients (pts) with high-risk hematologic malignancies. Donor availability remains a major limitation for many pts. The introduction of high-dose post-transplant cyclophosphamide (PTCy) has significantly improved the outcomes of pts undergoing haploidentical (HAPLO) stem cell transplants. The choice between a HAPLO or a one-antigen HLA mismatched unrelated donor (9/10 MUD) for pts lacking an HLA-matched donor remains unclear. Methods: We conducted a prospective non-randomized phase 2 clinical trial with two parallel arms, HAPLO (n=60) and 9/10 MUD (n=46) transplants, for pts with advanced hematologic malignancies or aplastic anemia who lacked an HLA-matched unrelated donor type at 10 loci (HLA-A, -B, -C, -DRB1, and -DQB1) using a MEL-based reduced-intensity conditioning regimen. The regimen included a single intravenous dose of MEL 140 mg/m2 (day -7), thiotepa 5 mg/kg (day -6), and four daily IV doses of fludarabine 40 mg/m2 (day -5 to day -2) (FM140). Thiotepa was intermittently available and was replaced by total body irradiation at a dose of 2 Gy on day -1. Pts >55 years (yr) old or with significant comorbidities received a lower MEL dose (100 mg/m2) (FM100). All pts with CD20-positive lymphoma received rituximab (375 mg/m2) on days -13, -6, +1 and +8. GVHD prophylaxis consisted of PTCy 50 mg/kg on day +3 and +4, and tacrolimus and mycophenolate for 6 and 3 months (mo), respectively. The stem cell source was unmodified bone marrow for both arms. Results: Patient characteristics are shown in Table 1. The median follow-up duration was 24 mo in the HAPLO arm and 29 mo in the 9/10 MUD arm. The cumulative incidence (CI) of neutrophil (ANC) recovery at day 45 was 95% and 98% in the HAPLO and 9/10 MUD arm, respectively. The median time to ANC recovery was 18 days in both arms; the median time to platelet recovery was 25 days in the HAPLO arm and 28 days in the 9/10 MUD arm. Primary graft failure developed in two pts in the HAPLO arm (one due to anti-donor HLA antibodies) and one patient in the 9/10 MUD arm. One pt in both arms developed mixed donor chimerism at day 100; otherwise, all pts in both arms achieved full (>95%) donor chimerism. Bone marrow was the graft source in all pts except 2 in the HAPLO arm and 8 in the 9/10 MUD arm who received a peripheral blood graft. The 1-yr overall and progression free survival were 70% and 60%, respectively, in the HAPLO arm (Fig. 1A) and 60% and 47%, respectively, in the 9/10 MUD arm (Fig. 1B). Day 100 CI of grade II-IV aGVHD and III-IV aGVHD were 28% and 3%, respectively, in the HAPLO arm versus 33% and 13%, respectively, in the 9/10 MUD arm; the 2-yr CI of chronic extensive GVHD was 13% and 14% in the two groups, respectively. The 1-yr CI of non-relapse mortality was 21% in the HAPLO arm and 31% in the 9/10 MUD arm, while the 1-yr relapse rate was 19% and 25% in the two groups, respectively. Conclusions: This study establishes PTCy, tacrolimus, and mycophenolate as an effective regimen for GVHD prevention in mismatched transplantation using both haploidentical and mismatched unrelated donor sources. Melphalan-based reduced-intensity conditioning is an effective regimen for a broad range of hematologic malignancies. Prospective randomized studies comparing haploidentical and unrelated donor sources are needed. Table 1. HAPLO (n=60) 9/10 MUD (n=46) Median Age, years (Range) 45 (20-63) 51 (20-64) Sex (M/F) 29/31 23/23 KPS ³90 53 (88%) 40 (87%) <90 7 (12%) 6 (13%) HCT-CI 0-3 50 (83%) 38 (83%) >3 10 (17%) 8 (17%) Disease Risk Index* Very high 5 (8%) 3 (7%) High 18 (30%) 15 (33%) Intermediate 29 (48%) 12 (26%) Low 8 (13%) 12 (26%) NA 0 4 (9%)** Conditioning Regimen FM100 20 (33) 18 (39%) FM140 40 (67%) 28 (61%) Diagnosis AML/MDS 33 (55%) 18 (39%) ALL 7 (11%) 5 (11%) Lymphoma 10 (17%) 13 (28%) Others 10 (17%) 10 (22%) Disease Stage Acute Leukemia CR1/CR2 24 (66%) 9 (56%) CR3 or higher/ CRpx 6 (17%) 5 (31%) Active disease 6 (17%) 2 (13%) Lymphoma CR 3 (30%) 8 (62%) PR 5 (50%) 3 (23%) Chemoresistant 2 (20%) 2 (15%) *Disease Risk Index by Armand et al; xCRp: Complete Remission with incomplete count recovery; **Patients had aplastic anemia. Figure 1. Figure 1. Disclosures Brammer: Celgene: Research Funding. Lee:Ziopharm: Equity Ownership; Cyto-Sen: Equity Ownership; Intrexon: Equity Ownership. Rezvani:Pharmacyclics: Research Funding. Alousi:Therakos, Inc: Research Funding." @default.
• W2559999242 created "2016-12-16" @default.
• W2559999242 creator A5002039083 @default.
• W2559999242 creator A5003367392 @default.
• W2559999242 creator A5007244861 @default.
• W2559999242 creator A5015342719 @default.
• W2559999242 creator A5016928938 @default.
• W2559999242 creator A5019752519 @default.
• W2559999242 creator A5026742949 @default.
• W2559999242 creator A5029237145 @default.
• W2559999242 creator A5029855695 @default.
• W2559999242 creator A5030891584 @default.
• W2559999242 creator A5033737136 @default.
• W2559999242 creator A5034104852 @default.
• W2559999242 creator A5035321251 @default.
• W2559999242 creator A5039574726 @default.
• W2559999242 creator A5048913229 @default.
• W2559999242 creator A5050962913 @default.
• W2559999242 creator A5053904944 @default.
• W2559999242 creator A5055885795 @default.
• W2559999242 creator A5068834306 @default.
• W2559999242 creator A5069460930 @default.
• W2559999242 creator A5072832956 @default.
• W2559999242 creator A5073053011 @default.
• W2559999242 creator A5074147173 @default.
• W2559999242 creator A5085076031 @default.
• W2559999242 creator A5086825472 @default.
• W2559999242 creator A5088175930 @default.
• W2559999242 creator A5089295627 @default.
• W2559999242 creator A5091083304 @default.
• W2559999242 date "2015-12-03" @default.
• W2559999242 modified "2023-09-30" @default.
• W2559999242 title "Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation" @default.
• W2559999242 doi "https://doi.org/10.1182/blood.v126.23.152.152" @default.
• W2559999242 hasPublicationYear "2015" @default.
• W2559999242 type Work @default.
• W2559999242 sameAs 2559999242 @default.
• W2559999242 citedByCount "2" @default.
• W2559999242 countsByYear W25599992422016 @default.
• W2559999242 countsByYear W25599992422017 @default.
• W2559999242 crossrefType "journal-article" @default.
• W2559999242 hasAuthorship W2559999242A5002039083 @default.
• W2559999242 hasAuthorship W2559999242A5003367392 @default.
• W2559999242 hasAuthorship W2559999242A5007244861 @default.
• W2559999242 hasAuthorship W2559999242A5015342719 @default.
• W2559999242 hasAuthorship W2559999242A5016928938 @default.
• W2559999242 hasAuthorship W2559999242A5019752519 @default.
• W2559999242 hasAuthorship W2559999242A5026742949 @default.
• W2559999242 hasAuthorship W2559999242A5029237145 @default.
• W2559999242 hasAuthorship W2559999242A5029855695 @default.
• W2559999242 hasAuthorship W2559999242A5030891584 @default.
• W2559999242 hasAuthorship W2559999242A5033737136 @default.
• W2559999242 hasAuthorship W2559999242A5034104852 @default.
• W2559999242 hasAuthorship W2559999242A5035321251 @default.
• W2559999242 hasAuthorship W2559999242A5039574726 @default.
• W2559999242 hasAuthorship W2559999242A5048913229 @default.
• W2559999242 hasAuthorship W2559999242A5050962913 @default.
• W2559999242 hasAuthorship W2559999242A5053904944 @default.
• W2559999242 hasAuthorship W2559999242A5055885795 @default.
• W2559999242 hasAuthorship W2559999242A5068834306 @default.
• W2559999242 hasAuthorship W2559999242A5069460930 @default.
• W2559999242 hasAuthorship W2559999242A5072832956 @default.
• W2559999242 hasAuthorship W2559999242A5073053011 @default.
• W2559999242 hasAuthorship W2559999242A5074147173 @default.
• W2559999242 hasAuthorship W2559999242A5085076031 @default.
• W2559999242 hasAuthorship W2559999242A5086825472 @default.
• W2559999242 hasAuthorship W2559999242A5088175930 @default.
• W2559999242 hasAuthorship W2559999242A5089295627 @default.
• W2559999242 hasAuthorship W2559999242A5091083304 @default.
• W2559999242 hasConcept C126322002 @default.
• W2559999242 hasConcept C141071460 @default.
• W2559999242 hasConcept C203014093 @default.
• W2559999242 hasConcept C2776694085 @default.
• W2559999242 hasConcept C2776755627 @default.
• W2559999242 hasConcept C2777408962 @default.
• W2559999242 hasConcept C2779972918 @default.
• W2559999242 hasConcept C28328180 @default.
• W2559999242 hasConcept C2911091166 @default.
• W2559999242 hasConcept C535046627 @default.
• W2559999242 hasConcept C54355233 @default.
• W2559999242 hasConcept C71924100 @default.
• W2559999242 hasConcept C86803240 @default.
• W2559999242 hasConceptScore W2559999242C126322002 @default.
• W2559999242 hasConceptScore W2559999242C141071460 @default.
• W2559999242 hasConceptScore W2559999242C203014093 @default.
• W2559999242 hasConceptScore W2559999242C2776694085 @default.
• W2559999242 hasConceptScore W2559999242C2776755627 @default.
• W2559999242 hasConceptScore W2559999242C2777408962 @default.
• W2559999242 hasConceptScore W2559999242C2779972918 @default.
• W2559999242 hasConceptScore W2559999242C28328180 @default.
• W2559999242 hasConceptScore W2559999242C2911091166 @default.
• W2559999242 hasConceptScore W2559999242C535046627 @default.
• W2559999242 hasConceptScore W2559999242C54355233 @default.
• W2559999242 hasConceptScore W2559999242C71924100 @default.
• W2559999242 hasConceptScore W2559999242C86803240 @default.
• W2559999242 hasLocation W25599992421 @default.
• W2559999242 hasOpenAccess W2559999242 @default.
• W2559999242 hasPrimaryLocation W25599992421 @default.
• W2559999242 hasRelatedWork W2060741445 @default.
• W2559999242 hasRelatedWork W2551725172 @default.

• next